Business Description
VERAXA Biotech AG is a German biotechnology company founded in 2021 and headquartered in Heidelberg, focused on developing targeted cancer treatments based on antibody science. The company builds and advances a pipeline of cancer drug candidates, including antibody-drug conjugates and related therapeutic formats, some of which are already in clinical testing. It operates a proprietary technology platform that supports the precise design and production of these treatments, which it also licenses to partners in the pharmaceutical and life sciences industries. VERAXA works with drug developers, research organizations, and other healthcare companies, offering collaborative development services that span the full journey from identifying a biological target to delivering a finished therapeutic candidate.
